Rachel S Rigo1, Laura E Levin1,2, Donald V Belsito1,2, Maria C Garzon1,2, Rachelle Gandica1,3, Kristen M Williams1,3. 1. Columbia University Irving Medical Center, New York, NY, USA. 2. Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA. 3. Department of Pediatrics, Columbia University Irving Medical Center, New York, NY, USA.
Abstract
BACKGROUND: Continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion (CSII) are the standard of care for type 1 diabetes in children. There is little reported on device-related skin complications and treatment options. This study documents cutaneous reactions to CGM and CSII devices in children and young adults with type 1 diabetes. METHODS: One hundred and twenty-one subjects (3-25 years) with type 1 diabetes and CGM and/or CSII use were recruited over a three-month period from the Naomi Berrie Diabetes Center at Columbia University Irving Medical Center. A five-question survey was completed for each subject detailing demographic data, diabetes management, and device-related skin complications. RESULTS: Sixty percent of subjects reported skin complications related to CGM and/or CSII use. Terms most frequently used to describe cutaneous reactions were "red," "itchy," "painful," and "rash." Subjects who used both CGM and CSII were more likely to report skin problems than those who used only CSII (odds ratio 2.9, [95% confidence interval: 1.2-6.7]; P = .015). There were no associations between skin complications and sex or race/ethnicity. Twenty-two percent of subjects with adverse skin event(s) discontinued use of a device due to their skin problem. Seven percent were evaluated by a dermatologist. Eighty-one percent used a range of products to treat their symptoms, with variable perceived clinical outcomes. CONCLUSIONS: Skin complications related to CSII or CGM devices are commonly reported in pediatric patients with type 1 diabetes and may lead to interruption or discontinuation of device use. Future studies are needed to elucidate the causes of these reactions and determine the best methods for prevention.
BACKGROUND: Continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion (CSII) are the standard of care for type 1 diabetes in children. There is little reported on device-related skin complications and treatment options. This study documents cutaneous reactions to CGM and CSII devices in children and young adults with type 1 diabetes. METHODS: One hundred and twenty-one subjects (3-25 years) with type 1 diabetes and CGM and/or CSII use were recruited over a three-month period from the Naomi Berrie Diabetes Center at Columbia University Irving Medical Center. A five-question survey was completed for each subject detailing demographic data, diabetes management, and device-related skin complications. RESULTS: Sixty percent of subjects reported skin complications related to CGM and/or CSII use. Terms most frequently used to describe cutaneous reactions were "red," "itchy," "painful," and "rash." Subjects who used both CGM and CSII were more likely to report skin problems than those who used only CSII (odds ratio 2.9, [95% confidence interval: 1.2-6.7]; P = .015). There were no associations between skin complications and sex or race/ethnicity. Twenty-two percent of subjects with adverse skin event(s) discontinued use of a device due to their skin problem. Seven percent were evaluated by a dermatologist. Eighty-one percent used a range of products to treat their symptoms, with variable perceived clinical outcomes. CONCLUSIONS: Skin complications related to CSII or CGM devices are commonly reported in pediatric patients with type 1 diabetes and may lead to interruption or discontinuation of device use. Future studies are needed to elucidate the causes of these reactions and determine the best methods for prevention.
Authors: R Paul Wadwa; Rosanna Fiallo-Scharer; Brandon Vanderwel; Laurel H Messer; Erin Cobry; H Peter Chase Journal: Diabetes Technol Ther Date: 2009-06 Impact factor: 6.118
Authors: Brienne D Cressey; Viswanath R Belum; Pamela Scheinman; Dianne Silvestri; Nancy McEntee; Vashti Livingston; Mario E Lacouture; Jonathan H Zippin Journal: Contact Dermatitis Date: 2016-08-31 Impact factor: 6.600
Authors: Anne Herman; Marie Baeck; Laurence de Montjoye; Magnus Bruze; Emil Giertz; An Goossens; Martin Mowitz Journal: Contact Dermatitis Date: 2019-08-27 Impact factor: 6.600
Authors: Richard I G Holt; J Hans DeVries; Amy Hess-Fischl; Irl B Hirsch; M Sue Kirkman; Tomasz Klupa; Barbara Ludwig; Kirsten Nørgaard; Jeremy Pettus; Eric Renard; Jay S Skyler; Frank J Snoek; Ruth S Weinstock; Anne L Peters Journal: Diabetologia Date: 2021-12 Impact factor: 10.122
Authors: Jennifer L Sherr; Lutz Heinemann; G Alexander Fleming; Richard M Bergenstal; Daniela Bruttomesso; Hélène Hanaire; Reinhard W Holl; John R Petrie; Anne L Peters; Mark Evans Journal: Diabetologia Date: 2022-10-06 Impact factor: 10.460